PT-141 Side Effects and Safety: What to Know Before Starting

PT-141 is bremelanotide, the active ingredient in the FDA-approved bremelanotide autoinjector (1.75 mg, for premenopausal women with hypoactive sexual desire disorder, or HSDD), which the FDA approved in 2019 for that use alone. In its two pivotal trials, 40% of women had nausea, 20% had flushing, and 11% had headache, and 18% stopped treatment because of side effects. Every dose raises blood pressure for up to about 12 hours, so the label rules out anyone with uncontrolled hypertension or known cardiovascular disease. The label also caps use at one dose per 24 hours and recommends no more than 8 doses per month. PT-141 that is not the approved product, whether from a compounding pharmacy or a peptide supplier, is not FDA approved.

What PT-141 is, and what the safety data actually cover

PT-141 was the development code name for bremelanotide, a synthetic peptide made of seven amino acids. It activates melanocortin receptors, a family of receptors found in the brain, the skin, and other tissues. The sibling guide on how PT-141 works covers the mechanism and the efficacy results in detail. This guide is about the other half of the decision: what can go wrong, how often, and for whom.

Nearly everything known about the safety of this drug comes from one product, given one way, to one group of people: the approved bremelanotide autoinjector, a 1.75 mg injection under the skin, studied in premenopausal women. That matters, because PT-141 is also supplied outside that product, by compounding pharmacies, peptide suppliers, and wellness clinics, in other doses and forms, and it is used by men and by postmenopausal women. For those uses, the safety numbers below are borrowed, not measured.

Regulatory status as of September 2026

As of September 2026, bremelanotide is FDA approved in the United States as a 1.75 mg autoinjector, marketed by Cosette Pharmaceuticals, for one use: premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). HSDD means low sexual desire that causes marked distress and is not explained by a medical or psychiatric condition, relationship problems, or a medication. The current label, posted on DailyMed in November 2025 with text last revised in March 2024, states two limitations of use plainly: the approved product is not indicated for HSDD in postmenopausal women or in men, and it is not indicated to enhance sexual performance.

PT-141 that is not the approved product, whether from a compounding pharmacy or a peptide supplier, and whether as an injection, a nasal spray, or any other form, is not FDA approved. The FDA does not review compounded drugs, or peptides sold by suppliers, for safety, effectiveness, or quality before they are sold. Any use in men, in postmenopausal women, or for performance is off-label, meaning outside what the FDA reviewed.

How large the evidence base is

The core evidence is a pair of identical phase 3 randomized, double-blind, placebo-controlled trials called RECONNECT (studies 301 and 302). Together they randomized 1,267 women, and 1,247 of them took at least one dose and make up the safety population: 627 on bremelanotide and 620 on placebo. The double-blind phase lasted 24 weeks, followed by a 52-week open-label extension in which 684 women chose to continue on the drug.

A 2022 review of the whole development program by Clayton and colleagues counted about 3,500 participants across 43 completed studies, from phase 1 through phase 3. That is a respectable safety database for an as-needed drug. It is not a large one by the standards of medicines taken by millions of people, and rare harms that occur in fewer than 1 in 1,000 users could easily have been missed.

Who was in the trials, and who was not

The women in RECONNECT were 19 to 56 years old, with a mean age of 39. About 86% were White and 12% were Black. They were generally healthy. The trials excluded women who were pregnant or nursing, women diagnosed with or treated for depression, psychosis, bipolar disorder, or substance abuse in the prior 6 months, and women taking antidepressants, mood stabilizers, benzodiazepines, and several other psychiatric medicines in the prior 3 months.

Use was also light. Most participants injected two to three times per month and no more than once a week, and the median was 10 injections over the 24-week blinded phase. So the published frequencies describe occasional use by healthy premenopausal women. They say much less about frequent use, older users, men, or people with heart, kidney, liver, or psychiatric conditions.

Why a drug for desire causes nausea, flushing, and darker skin

Bremelanotide is not selective. According to the prescribing information, it activates several melanocortin receptor subtypes, in this order of potency: MC1R, MC4R, MC3R, MC5R, MC2R. At the approved dose, the label says binding to MC1R and MC4R is the most relevant. The label is also candid that the mechanism by which the drug improves HSDD is unknown.

That lack of selectivity explains much of the side-effect profile:

• MC4R is found on neurons in many areas of the brain. It is the receptor believed to influence sexual desire. Drugs that bind MC4R may raise blood pressure, which is why researchers studied this effect so closely.
• MC1R sits on melanocytes, the pigment cells of the skin. Activating it increases melanin production. This is the basis of the skin darkening described below.
• Slowed stomach emptying. The label reports that bremelanotide may slow gastric emptying, which is the likely reason it lowers the absorption of some oral medicines. Whether this also contributes to the nausea has not been established.

The drug moves through the body quickly. After an injection under the skin, blood levels peak at about 1 hour and the half-life (the time for the blood level to fall by half) is about 2.7 hours. Most side effects follow the same clock: they start within an hour or so and fade over a few hours. Bioavailability by injection is about 100%, which is one reason the injection replaced an earlier nasal spray whose absorption varied widely from person to person.

The common side effects, with frequencies from the label

The table below comes from the adverse reactions section of the FDA label for bremelanotide. It pools both RECONNECT trials and lists reactions reported by at least 2% of women on the drug and more often than on placebo. About 7 in 10 events were rated mild (31%) or moderate (40%), and most were temporary.

Reactions seen in fewer than 2% of women, but still more often than with placebo, included upper abdominal pain, diarrhea, muscle and joint pain, restless legs, a runny nose, raised creatine phosphokinase (a muscle enzyme measured on blood tests), increased blood pressure, pain in a limb, and focal skin hyperpigmentation.

Nausea

Nausea is the defining side effect of this drug. Four in 10 women on the approved product reported it at some point, compared with about 1 in 100 on placebo. It is the main reason people quit: 8% of women on the drug left the trials early because of nausea, and no one on placebo did.

When it starts and how long it lasts

The label reports a median onset within 1 hour of the injection and a duration of about 2 hours. The published trial report gives a median onset of 30 minutes and a median duration of 2.4 hours. About 98% of nausea episodes were rated mild or moderate, and most resolved without treatment. Still, 13 women (2.1%) had nausea rated severe, and the patient leaflet warns that nausea can be severe and can last longer than 2 hours in some people.

The first dose is the worst

Nausea was most common after the first injection, when 21% of women reported it. After later doses the rate fell to about 3% per dose. The label summarizes this as nausea improving for most patients with the second dose. Put differently, the 40% figure is the share of women who had nausea at least once over 24 weeks. It is not the chance of nausea with every injection.

Do anti-nausea medicines help?

In the phase 3 trials, 13% of women on the drug took an anti-nausea medicine. The label allows prescribers to consider one for people who are bothered by nausea but want to continue. One popular idea has been tested and failed: in a phase 4 placebo-controlled study of 228 healthy women, taking 8 mg of oral ondansetron 30 minutes before the injection did not reduce nausea, and the label says this pre-treatment is not recommended. Taking ondansetron after nausea begins has not been formally studied.

Because the label lets each person choose the timing of the dose based on how they experience the effect and the side effects, some people plan around the first two hours. That is a conversation for your prescriber, not something the trials tested head to head.

Flushing and hot flushes

About 1 in 5 women had flushing, a sudden warmth and redness, usually of the face and upper body. Hot flush was recorded separately in 2.7%. None of the flushing events was serious, fewer than 1% were severe, and 1% of women stopped the drug because of it. In a small crossover study of 24 healthy adults using an intranasal form, flushing was no more common when bremelanotide was combined with alcohol than with bremelanotide alone.

Headache

Headache affected 11% of women on bremelanotide and 2% on placebo. Most were mild. There was one notable exception: a participant was hospitalized overnight with vomiting and an intractable headache that investigators judged related to the drug. Headache led 2% of women to stop treatment. A new, severe headache after a dose deserves attention rather than dismissal, because this drug also raises blood pressure.

Injection site reactions

Pain, redness, bruising, itching, numbness, or tingling where the needle went in was reported by 13.2% of women on bremelanotide and 8.4% on placebo. The small gap between the two groups suggests that much of this comes from the injection itself, not the drug. In the earlier 12-week dose-finding trial, none of the injection site reactions was severe, and none came with signs of a wider allergic reaction.

How many people stopped because of side effects

This may be the most useful single number for judging tolerability. In the blinded phase, 18% of women on bremelanotide stopped because of an adverse reaction, compared with 2% on placebo. The leading reasons were nausea (8%), headache (2%), vomiting (1%), flushing (1%), and injection site reactions (1%).

Dropout for any reason was high and lopsided. In study 301, 41.9% of the bremelanotide group withdrew versus 16.0% of the placebo group; in study 302 it was 43.8% versus 28.4%. According to the developers' own safety review, 70% of the women who finished the blinded phase on bremelanotide went on to the open-label year, compared with 87% of those who finished on placebo. Of the 684 women who entered that extension, 272 completed it. The honest reading is that a meaningful share of people who try this drug decide it is not worth continuing, and side effects are a big part of why.

Serious adverse events were uncommon: 1.1% of women on bremelanotide and 0.5% on placebo. There were no deaths in the development program. During the 52-week extension, the pattern looked the same as in the blinded phase, with nausea (40.4%), flushing (20.6%), and headache (12.0%) leading the list, and investigators reported no new safety signals. That extension had no placebo group, so it cannot separate drug effects from background events.

The blood pressure rise, and who it excludes

Every dose of bremelanotide temporarily raises blood pressure and slows the heart rate. This is not an occasional side effect. It is a predictable drug effect that happens to everyone to some degree, and it shapes who should not use PT-141 at all.

What the measurements showed

The prescribing information puts the maximum average increases at 6 mmHg in systolic pressure (the top number) and 3 mmHg in diastolic pressure (the bottom number), peaking 2 to 4 hours after the dose. Heart rate fell by up to 5 beats per minute. Both usually returned to baseline within 12 hours.

The most detailed data come from a phase 2 randomized trial by White and colleagues, in which 397 premenopausal women wore 24-hour ambulatory blood pressure monitors. At the 1.75 mg dose, average systolic pressure rose about 3 mmHg more than placebo in the first 4 hours, with a fall in heart rate of 4.6 to 4.7 beats per minute. Peak increases typically lasted less than 15 minutes. Averages hide individuals, though. One of the 99 women on the 1.75 mg dose had a systolic reading of 170 mmHg lasting 30 minutes. No one had a sustained reading above 180 mmHg. About 7% of participants were withdrawn for meeting preset blood pressure criteria, but that share was similar across all groups, including placebo (6% on placebo, 7% on 1.75 mg).

In a separate open-label study of 127 women who injected daily, average daytime pressure after 8 days was up 1.9 mmHg systolic and 1.7 mmHg diastolic. The label notes that repeat daily dosing 24 hours apart for up to 16 days did not produce additive blood pressure effects.

Who the label excludes

The approved product's label lists one formal contraindication, a situation in which the drug should not be used: uncontrolled hypertension or known cardiovascular disease. Beyond that, the label says the drug is not recommended for people at high risk for cardiovascular disease, and it tells prescribers to consider cardiovascular risk and make sure blood pressure is well controlled before starting and periodically during treatment.

The FDA's reviewers explained their reasoning in the approval documents. A few millimeters of mercury for a few hours, up to 8 times a month, is not expected to appreciably raise cardiovascular risk in premenopausal women, who are generally at low risk. The same small rise could matter in someone whose arteries or heart are already compromised. That is also the stated reason for the limitation of use in postmenopausal women, who have a higher background rate of cardiovascular disease and showed more variable drug exposure.

In practical terms, the blood pressure effect is a reason for extra caution or exclusion if you have:

• High blood pressure that is not controlled, whether or not you take medicine for it.
• Known heart or blood vessel disease, such as coronary artery disease, a prior heart attack or stroke, or heart failure.
• Several strong cardiovascular risk factors that put you in a high-risk category, a judgment your prescriber makes.
• Never had your blood pressure checked recently. A normal reading is the starting point for a safe prescription.

Why the 24-hour spacing rule exists

The label says the effectiveness of two doses within 24 hours has not been established and that doses taken close together may increase the risk of additive effects on blood pressure. This was not a theoretical worry: FDA reviewers noted that 3.9% of trial participants took consecutive doses less than 12 hours apart, which is part of why the spacing rule is written into the label.

What the trials cannot tell you

The blood pressure studies enrolled women whose pressure was normal or controlled; women with readings of 140/90 mmHg or higher at screening were excluded. The authors of the ambulatory monitoring study named the exclusion of women with uncontrolled readings as an important limitation, and a peer reviewer's comment published with the paper noted that no one had evaluated whether women with treated, controlled hypertension respond differently from women without hypertension. There is no long-term cardiovascular outcomes trial of bremelanotide, and there are no comparable monitoring studies of non-approved PT-141 at the doses and frequencies some clinics use.

Focal hyperpigmentation: darkening of the skin and gums

Focal hyperpigmentation means patches of darker skin. With bremelanotide it has appeared on the face, the gums (gingiva), and the breasts. It follows directly from the drug's action on MC1R, the receptor on pigment cells.

How common it is depends on how often you dose

In the phase 3 trials, where women used up to 8 doses per month and most used far fewer, focal hyperpigmentation was reported in 1% of women on bremelanotide and in no one on placebo. In a clinical study of daily dosing, the picture changed sharply: 38% of participants developed focal hyperpigmentation after 8 consecutive days, and among those who continued for 8 more days, another 14% developed new pigment changes. This dose-frequency relationship is one of the two stated reasons the label recommends no more than 8 doses per month.

Who is at higher risk

The label says people with dark skin were more likely to develop focal hyperpigmentation. FDA reviewers also noted that it occurred more often in Black participants. Because only 12% of trial participants were Black, the estimate of how much higher the risk is remains imprecise.

It may not go away

This is the part people tend to underestimate. The label states that resolution was not confirmed in all patients after stopping the drug. The FDA review is more specific: reversibility was documented in about half of cases during follow-up. The patient leaflet says it directly: darkening of the skin may not go away, even after you stop. The label advises prescribers to consider discontinuing the drug if hyperpigmentation develops.

What about moles and melanoma?

FDA reviewers wrote that there did not appear to be an increased risk of developing atypical moles or of moles turning malignant in the trials, while cautioning that the duration and extent of exposure limits definitive conclusions. The label reports no significant increase in tumors in 2-year rat and mouse studies. That is reassuring but not the same as long-term human data. Reviewers asked that patients be told to seek care if pigmented areas develop or change in ways that concern them, which is sensible advice for anyone on this drug.

The dosing limits in the label, and the reasons behind them

This section describes what the FDA-approved label says. It is not a dosing recommendation for you; your prescriber sets that. The limits are worth understanding because each one is tied to a specific safety finding, and because PT-141 regimens outside the approved product sometimes ignore them.

The trial protocols allowed up to 12 doses per month, but almost nobody used that many, so the FDA capped its recommendation at 8, where there was actual safety experience. On overdose, the label says none has been reported, and that nausea, focal hyperpigmentation, and more pronounced blood pressure increases are more likely at higher doses. Blood levels stop rising proportionally at higher doses and plateau at around 7.5 mg, roughly 4.3 times the approved dose, but that pharmacology finding is not evidence that higher doses are safe.

The label also tells users to inspect the solution and discard it if it is cloudy, discolored, or contains particles. That instruction applies with even more force to multi-dose vials, whether from a compounding pharmacy or a peptide supplier, which do not come in a sealed, single-dose autoinjector.

Drug interactions: naltrexone and other oral medicines

The drug interactions described in the label come from slowed stomach emptying, which can delay and reduce the absorption of medicines taken by mouth. In clinical pharmacology studies, most tested oral drugs were not affected to a clinically relevant degree. Two were: naltrexone and indomethacin.

Naltrexone

Naltrexone blocks opioid receptors. It is taken by mouth to treat alcohol use disorder and opioid use disorder, and it is one of the two ingredients in the naltrexone/bupropion combination product used for weight loss. In an interaction study in healthy women taking naltrexone and bupropion at steady state, a dose of bremelanotide cut the peak naltrexone level by 64% and total naltrexone exposure by 40%, and delayed the peak by about 3 hours. Bupropion levels also fell, by 36% at peak and 20% overall.

The label's instruction is to avoid the approved product with an orally administered naltrexone product that is intended to treat alcohol or opioid addiction, because a failure of naltrexone treatment can have severe consequences. FDA reviewers judged that the occasional dip was unlikely to undermine long-term weight loss with the naltrexone/bupropion combination product, and that the monthly extended-release naltrexone injection was unlikely to be affected because it does not pass through the stomach. If you take naltrexone in any form, including low-dose naltrexone from a compounding pharmacy, your prescriber needs to know before PT-141 is considered.

Other oral medicines

The label advises avoiding bremelanotide while taking oral drugs that depend on reaching a threshold concentration to work, and gives antibiotics as the example. It also suggests considering stopping it if an oral medicine that needs to act quickly, such as a pain reliever like indomethacin, seems delayed. Anyone who relies on a time-critical oral medicine should raise this with their prescriber or pharmacist.

Alcohol

A randomized crossover study in 12 men and 12 women tested a 20 mg intranasal dose of bremelanotide with a moderate amount of alcohol, about three standard drinks for a 70 kg person. Alcohol did not change bremelanotide blood levels, and there was no excess of low blood pressure on standing. Headache was more common with the combination than with bremelanotide alone, at a rate similar to alcohol alone. In RECONNECT, side-effect patterns did not differ by how much alcohol participants reported drinking. This is limited evidence from a small study using a different form of the drug, but it found no specific danger signal.

Pregnancy, breastfeeding, and contraception

The label says use during pregnancy is not recommended, advises women who can become pregnant to use effective contraception while using the drug, and says to stop the drug if pregnancy is suspected. In the trials, all participants in heterosexual relationships were required to use effective contraception.

The human data are thin. There were 7 pregnancies among more than 1,057 women treated for up to 12 months: five full-term live births, one miscarriage, and one unknown outcome, with no major birth defects reported. That is far too few to judge risk. The concern comes from animal studies. In pregnant dogs, daily dosing at exposures 16 times the human dose or higher increased loss of embryos, and in mice, developmental delays appeared in offspring at about 125 times the human exposure. Crucially, researchers never identified a dose low enough to have no effect in either species, so a safe margin is not known.

For breastfeeding, the label says there is no information on whether bremelanotide passes into human milk, affects a breastfed infant, or affects milk production. Safety and effectiveness have not been established in children or in older adults.

Rare and uncertain risks

One case of acute hepatitis

During the open-label extension, one woman developed acute hepatitis. The label says she had received 10 doses of the drug over a year, while the published trial report says she stopped after her 20th injection. Per the label, her liver enzymes rose to more than 40 times the upper limit of normal and her bilirubin to 6 times the upper limit. Her liver tests returned to normal 4 months after she stopped the drug. No other cause was found, so the label says a role for bremelanotide could not be definitively excluded. There was no broader pattern of liver enzyme abnormalities in the program. The NIH LiverTox database rates bremelanotide as a possible rare cause of clinically apparent liver injury. Yellowing of the skin or eyes, dark urine, or unusual fatigue after use should be reported promptly.

Kidney and liver impairment

After a radiolabeled dose, about 65% of the radioactivity was recovered in urine. Drug exposure was 1.2 times higher in mild kidney impairment, 1.5 times higher in moderate impairment, and 2 times higher in severe impairment. In liver impairment, exposure was 1.2 times higher when mild and 1.7 times higher when moderate; severe liver impairment was not studied. The label recommends no dose change for mild to moderate impairment but advises caution in severe kidney or liver impairment, because side effects such as nausea and vomiting may be more frequent and more severe.

Mood and mental health

The trials monitored depression and suicidal thinking and found no clinically significant effect. Keep in mind that women with recent depression or on antidepressants were excluded, so the drug's safety in people with active psychiatric conditions, or alongside those medicines, was not established in RECONNECT.

Long-term and frequent use

The longest controlled experience is 24 weeks, with an additional uncontrolled year, at a typical rate of two to three doses per month. Participants could be on the drug for up to 18 months in total. There are no data on years of use, and very little on frequent use. Anyone describing PT-141 as proven safe for long-term, several-times-a-week use is going beyond the evidence.

Men, postmenopausal women, and other off-label use

Non-approved PT-141 is often marketed to men, usually for erectile dysfunction or low libido, although no reliable data describe how widely it is used. No bremelanotide product is approved for men, and the FDA label for bremelanotide specifically says it is not indicated for them.

The evidence in men is early-stage and mostly used a nasal spray that was never approved. In early-phase studies run by the original developer, intranasal doses above 7 mg produced erections in healthy men and in men with mild to moderate erectile dysfunction, with flushing and nausea as the most common side effects, and a 19-man crossover study found a greater erectile response when a low intranasal dose was added to sildenafil. A larger randomized trial of 342 men who had not responded to sildenafil reported benefit, but the journal that published it issued an expression of concern about the paper in 2023, so it should not be relied on. There are no phase 3 trials in men.

The nasal spray program also explains some of the caution around this drug. According to published accounts from the investigators, intranasal absorption varied widely, exposing some people to higher levels than needed and a heightened risk of side effects including blood pressure elevation. The FDA raised concerns after those studies, and development moved to an injection under the skin, tested with intensive blood pressure monitoring. The FDA accepted the blood pressure effect of the approved product partly because premenopausal women are generally at low cardiovascular risk. That reasoning does not automatically carry over to men, especially older men or those with heart disease or risk factors for it, and the question has not been studied properly in them.

For postmenopausal women, the FDA cited a higher background rate of cardiovascular disease, more variable drug exposure, and unestablished efficacy as the reasons for the limitation of use.

PT-141 outside the approved product: what changes

Some people who use PT-141 never see an autoinjector. They receive a multi-dose vial and syringes, or a nasal spray, either from a compounding pharmacy, often through a telehealth service, or from a peptide supplier through a peptide therapy clinic that reconstitutes it. Several things change in that situation.

The legal footing for the compounding route

This applies to the compounding route only. Under section 503A of federal law, a state-licensed pharmacy can compound with a bulk drug substance if it has a USP monograph, is a component of an FDA-approved drug, or appears on the FDA's 503A bulks list. Bremelanotide is the active ingredient of an approved drug, so it appears to fit the second route, unlike peptides such as BPC-157 that have no approved version. That is a reading of the FDA's general framework; the FDA has not made a statement about compounding bremelanotide specifically. As of the FDA's April 2026 update to its list of nominated bulk substances that may present significant safety risks (Category 2), bremelanotide was not on that list. Federal law also restricts compounders from regularly making what are essentially copies of a commercially available drug, and the approved bremelanotide product is commercially available. How that applies to a given product depends on the formulation and the documented medical need, which is a question for the prescriber and pharmacy.

Legal to compound does not mean FDA approved

The FDA states that compounded drugs are not FDA approved, meaning the agency does not verify their safety, effectiveness, or quality before they are marketed. It warns that poor compounding practices can lead to contamination or to a product containing too much or too little active ingredient, and says compounded drugs should only be used when an approved drug cannot meet a patient's medical needs. Pharmacies compounding under section 503A are not held to the current good manufacturing practice standards that apply to drug manufacturers and to registered outsourcing facilities. The FDA also notes that people who buy compounded drugs online may not know who actually made the product.

The peptide-supplier route, and what Rx2BFIT does

PT-141 that comes from a peptide supplier rather than a compounding pharmacy is outside FDA review in the same way. Rx2BFIT does not dispense the approved autoinjector. Its PT-141 comes from a supplier whose batches are tested by an independent laboratory for identity and purity, with a certificate of analysis on file, and is reconstituted in the office under Dr. Patel's supervision. It is not an FDA-approved medication, and that, along with the known risks, is reviewed with every patient before starting.

Different doses, routes, and schedules

All of the frequencies in this article come from a single 1.75 mg dose injected under the skin. Non-approved products may be prescribed at other doses, and non-injected forms have no phase 3 safety data behind them. The one route with a documented history, the nasal spray, was not pursued: the FDA's review says the sponsor dropped that route because exposure was low and highly variable, and investigators report that the FDA had raised concerns after the early intranasal studies. A multi-dose vial also removes the built-in limit of a single-dose pen, which makes it easier to exceed one dose per 24 hours or 8 per month. The label's own overdose section says that nausea, hyperpigmentation, and larger blood pressure increases become more likely as the dose goes up.

Melanotan II is not PT-141

PT-141 was developed as an analog of Melanotan II, an unapproved peptide sold online for tanning, and the two are sometimes confused or marketed together. They should not be. The FDA lists Melanotan II among bulk substances that may present significant safety risks in compounding, citing published case reports of melanoma, a serious brain condition called posterior reversible encephalopathy syndrome, sympathomimetic toxicity (a dangerous overstimulation of the nervous system), and priapism. A dermatology review counted four case reports of melanomas arising from existing moles during or shortly after melanotan use, while noting that a causal link is unproven. A 2019 case report described a man who needed emergency treatment for priapism, an erection that will not go down, after injecting melanotan, and who had not recovered erectile function 4 weeks later. These are case reports about a different, unregulated product, not findings about bremelanotide. They are a reason to be sure of exactly what is in a vial labeled as a melanocortin peptide.

When to call your prescriber, and when to seek urgent care

Most side effects of PT-141 are unpleasant, short, and not dangerous. Some situations call for more.

Seek emergency care right away for symptoms that could signal a cardiovascular or severe allergic event after a dose:

• Chest pain or pressure, shortness of breath, or fainting.
• A sudden severe headache, especially with vision changes, confusion, weakness on one side, or trouble speaking.
• Swelling of the face, lips, or throat, or trouble breathing.
• In men using PT-141 off-label, a prolonged or painful erection that will not go down.

Contact your prescriber promptly if you have:

• Nausea or vomiting that is severe, lasts well beyond a few hours, or keeps you from holding down fluids or other medicines.
• New dark patches on your face, gums, or breasts, or a mole that changes.
• Home blood pressure readings that are higher than usual, or a pounding or unusually slow heartbeat.
• Yellowing of the skin or eyes, dark urine, or unusual fatigue.
• A positive pregnancy test or a suspected pregnancy.
• No improvement in desire after about 8 weeks of use.

Side effects of the approved product can be reported to the FDA's MedWatch program at 1-800-FDA-1088.

Myths and realities

Myth: peptides are natural, so side effects are minimal

Bremelanotide is a synthetic peptide, and in its pivotal trials 40% of women had nausea and 18% quit because of side effects, compared with 2% on placebo. Being a peptide says nothing about tolerability.

Myth: the blood pressure effect only matters if you feel it

The rise in blood pressure occurs after every dose and usually causes no symptoms. That is exactly why the label asks prescribers to check blood pressure and cardiovascular risk before starting and periodically afterward, not to wait for symptoms.

Myth: skin darkening always fades when you stop

Reversal was documented in only about half of trial cases during follow-up, and the patient leaflet warns that darkening may not go away.

Myth: taking an anti-nausea pill beforehand solves the nausea

The one strategy that was formally tested, ondansetron 30 minutes before the injection in 228 women, did not reduce nausea. What does help is time: nausea is much less common after the first dose or two.

Myth: PT-141 from a compounding pharmacy or peptide supplier is the same thing as the approved product

The active molecule may be the same, but the product is not. Dose, purity, sterility, and delivery form are not FDA reviewed for non-approved versions, and non-injected forms have not been through phase 3 safety studies.

Myth: more frequent dosing works better

No trial shows that. What the daily-dosing study did show is a jump in hyperpigmentation from 1% to 38% within 8 days.

Questions to ask your prescriber

1. Is my blood pressure well controlled, and when was it last measured? Do I have any cardiovascular condition or risk level that rules this drug out?
2. Am I being prescribed the FDA-approved autoinjector or a non-approved product? If it is not the approved product, where does it come from, is each batch tested by an independent laboratory for identity and purity, can I see the certificate of analysis, and why is the approved product not appropriate for me?
3. What dose and route are you prescribing, and what evidence supports that dose and route specifically?
4. Do any of my medicines conflict with it, especially naltrexone, the naltrexone/bupropion combination product, antibiotics, or pain medicines I need to work quickly?
5. What is the plan if the first dose makes me very nauseated?
6. I have a darker skin tone. How should that change my thinking about hyperpigmentation, and what should I watch for?
7. What contraception is appropriate while I use this?
8. How will we judge whether it is working, and when would we stop?
9. If I am a man or past menopause, what is the evidence for someone like me, and what monitoring do you recommend?

A prescriber who is comfortable with these questions, checks your blood pressure, and reviews your medication list is following the label. One who offers PT-141 without any of that is not. General background on this medication and how it is used is on the PT-141 treatment page.

This is general information, not medical advice. Whether a treatment is right for you is determined by a licensed provider after an evaluation.